Business Wire - October 31, 2002

HIV produces copious amounts of toxic surface proteins known as gp120. Gp120 damages nerve cells and white blood cells involved in the body's natural immune defenses. The toxic activity of gp120 appears to be a major factor in the degradation of the immune system and the subsequent development of AIDS.

Aethlon indicated that AEMD-45, the company's lead treatment candidate now removes up to 90 percent of gp120 from HIV infected blood in 1 hour, almost 4 times faster than earlier systems in development. AEMD-45 also proved capable of removing up to 100 percent of the toxin in 4 hours, the equivalent time of a typical dialysis session. Aethlon expects to have updated data on whole HIV removal in the near future. AEMD-45 is part of Aethlon's expansive platform technology known as the Hemopurifier(TM).

Richard Tullis, Ph.D., Aethlon's chief scientific officer stated: "The significant improvement in our ability to remove the gp120 toxin should be recognized as important news for those who treat HIV and AIDS and the individuals who are infected with this virus."

The new data was derived as a result of ongoing testing of various antibodies when immobilized within the AEMD-45 Hemopurifier. In addition to analyzing toxin removal, the company takes into consideration commercialization issues such the costs and availability of antibody production to fulfill potential market requirements.

About Aethlon Medical

Aethlon Medical develops therapeutic devices that treat HIV/AIDS, Hepatitis-C, and other infectious diseases. In pre-clinical testing, Aethlon's lead product, AEMD-45 removed 55 percent of HIV from human blood in three hours and in excess of 85 percent in 12 hours. The AEMD-45 therapeutic device, like all product offerings from Aethlon Medical, is developed from an expansive platform technology known as the Hemopurifier(TM), which employs a proprietary method to increase the capability of FDA cleared artificial kidneys (dialysis cartridges) to remove targeted intoxicants from the blood. In the case of AEMD-45, dialysis cartridges are modified to mimic the immune system's response to clear infectious virus from circulation before healthy cells are infected. AEMD-45 is designed to fill the urgent need for new treatments that are effective in reducing viral load, decrease the likelihood of treatment resistance, and treat without the toxic side-effects associated with AIDS drugs. For more information, visit the company's Web site at www.AethlonMedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to raise capital when needed, the company's ability to complete the development of its planned products, the ability of the company to obtain FDA and other regulatory approvals permitting the sale of its products, the company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the company's Securities and Exchange Commission filings.

CONTACT: Aethlon Medical Inc.

James A. Joyce, 858/456-5777

info@aethlonmedical.com

SOURCE: Aethlon Medical Inc.

021031
BW021017

Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .